EUVIMEDEUVIMED entdecken
Open Access

Projecting the Impact and Costs of Near Point-of-Care Tuberculosis Screening Assays in Community-based Active Case Finding

Jason R Andrews, Emily A Kendall, Adithya Cattamanchi, Claudia M Denkinger, Payam Nahid iD, Sourya Shrestha, Florian M Marx iD, David Dowdy, Sabine Hermans iD, Frank Cobelens

Clinical Infectious Diseases · 06.11.2025 · 81 (4) · 776-784

DOI: 10.1093/cid/ciaf395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 17.07.2025. Verfasst von Jason R Andrews und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Tuberculosis, Mass Screening, Point-of-Care Systems, Point-of-Care Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Community-based active case finding (ACF) may reduce tuberculosis incidence and mortality but is not widely implemented due to resource constraints. How novel screening test characteristics would affect the impact and costs of ACF strategies is not clear.

Methods

We developed mathematical models of tuberculosis natural history and transmission, calibrated to data from 3 high tuberculosis burden countries (India, Vietnam, and the Philippines) and simulated the impact of annual community-based ACF programs. We compared annual screening, with or without an initial symptom screen, for 10 years with 2 hypothetical screening assays based on target product profile minimum targets: a low complexity (reaches 60% of the population) test with high sensitivity (90%) and moderate specificity (80%) costing $3; and a near point-of-care (reaches 80% of the population) test with moderate sensitivity (55%) and high specificity (98%) costing $2. We projected reductions in tuberculosis incidence, mortality, and costs under each scenario.

Results

Annual screening with a low-complexity, high-sensitivity screening assay was projected to reduce tuberculosis mortality by 24%–38%, at an annual cost of $5.04–$5.83 per capita. Annual screening with a near-point-of-care, moderate-sensitivity assay was projected to achieve comparable reductions in mortality (24%–42%) at $3.49–$3.63 per capita. Symptom-based screening would yield more modest reductions in tuberculosis mortality (17%–24%) at an annual cost of around $1 per capita.

Conclusions

Near point-of-care, moderate-sensitivity screening assays for tuberculosis could achieve substantial impact on tuberculosis mortality—equivalent to that of high-sensitivity assays and at lower cost—if they can be performed at scale in community settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisMass ScreeningPoint-of-Care SystemsPoint-of-Care TestingHumansVietnamPhilippinesIndiaSensitivity and SpecificityIncidenceModels, Theoretical

Stichwörter der Autor:innen

case findingcommunity-baseddiagnosticsscreeningtuberculosis

Autor:innen und Institutionen

  • Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Global Health and Amsterdam Public Health, Amsterdam University Medical Centers Location University of Amsterdam, Amsterdam, The Netherlands.
  • Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Pulmonary Diseases and Critical Care Medicine, UC Irvine, Irvine, California, USA.
  • UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
  • Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: Payam Nahid, Florian M Marx, Sabine Hermans

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Andrews, J. R., Kendall, E. A., Cattamanchi, A., Denkinger, C. M., Nahid, P., Shrestha, S., Marx, F. M., Dowdy, D., Hermans, S., & Cobelens, F. (2025). Projecting the Impact and Costs of Near Point-of-Care Tuberculosis Screening Assays in Community-based Active Case Finding. Clinical Infectious Diseases, 81(4), 776-784. https://doi.org/10.1093/cid/ciaf395

Vancouver

Andrews JR, Kendall EA, Cattamanchi A, Denkinger CM, Nahid P, Shrestha S, et al. Projecting the Impact and Costs of Near Point-of-Care Tuberculosis Screening Assays in Community-based Active Case Finding. Clinical Infectious Diseases. 2025;81(4):776-784. doi:10.1093/cid/ciaf395

BibTeX
@article{Andrews2025,
  author = {Andrews, Jason R and Kendall, Emily A and Cattamanchi, Adithya and Denkinger, Claudia M and Nahid, Payam and Shrestha, Sourya and Marx, Florian M and Dowdy, David and Hermans, Sabine and Cobelens, Frank},
  title = {Projecting the Impact and Costs of Near Point-of-Care Tuberculosis Screening Assays in Community-based Active Case Finding},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {4},
  pages = {776--784},
  doi = {10.1093/cid/ciaf395}
}
Kostenlos starten →